Development Center for Biotechnology—Institute of Pharmaceutics
The Development Center for Biotechnology (DCB) was established as a nonprofit research institution in 1984 funded by the public and private sectors. Located in the National Biotechnology Research Park, DCB persists in technology innovation, industrial development, and talent cultivation as its core values, with the expertise of preclinical development and translational medicine research, and play a vital role in drug commercialization to drive the development of the biotechnology industry in Taiwan. The DCB focuses on research and development (R&D) of novel drugs and treatment. We offer technology licensing services as well as integration services from commissioned research to business promotion, in addition to fostering international collaborations.

The DCB develops new drugs either independently or collaboratively with academia and industry. To date, the DCB has obtained over 10 investigational New Drug application approvals and has successfully transferred to industry through licensing. Accordingly, these drugs are under development through clinical trials. Institute of Pharmaceutics of DCB possesses expert team with rich experiences in chemical synthesis and drug development, can provide small molecule drug development services and in vitro activity characterization with high quality. The Institute of Pharmaceutics consists of two development groups. The Medicinal Chemical group provides platform technologies for the medicinal chemistry synthesis, process development for APIs and intermediates, and custom synthesis. The Bioactivity Identification group is responsible for preclinical In vitro drug activity studies, evaluation of the mechanism of action, and safety pharmacology tests. The research teams can perform commissioned research on developing new small molecular drugs as well as integrate with DCB business development teams to offer customized services to help accelerate commercialization of new drugs.

The Institute of Pharmaceutics aims to become the “best partner” in the small molecular drug development. Through years of accumulative capabilities in innovative drug R&D that align with the trend of international pharmaceutical development, DCB strives to provide a better quality of life and health for patients. The Institute of Pharmaceutics committed to four major disease fields, including cancer, autoimmune, metabolic (such as diabetes) and neurologic diseases. Among the DCB developed drugs which are in clinical trials, ON101 (DCB-WH1)for diabetic foot ulcer treatment had been gained an outstanding achievement. ON101 had been exclusively licensed out to MicroBio/Oneness Biotech. ON101 is currently under clinical phase III clinical trial in US and China and has registered for the New Drug Application (NDA) to TFDA in Taiwan. These results all demonstrate that Institute of Pharmaceutics owns pre-clinical development and successful experiences and is one of the few comprehensive drug discovery and development institutes in Taiwan.